Precision BioSciences, Inc. (DTIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
DTIL POWR Grades
- DTIL scores best on the Value dimension, with a Value rank ahead of 59.21% of US stocks.
- The strongest trend for DTIL is in Momentum, which has been heading down over the past 29.7142857142857 weeks.
- DTIL ranks lowest in Momentum; there it ranks in the 5th percentile.
DTIL Stock Summary
- Precision Biosciences Inc's stock had its IPO on March 28, 2019, making it an older stock than only 4.81% of US equities in our set.
- Price to trailing twelve month operating cash flow for DTIL is currently 81.83, higher than 94.63% of US stocks with positive operating cash flow.
- For DTIL, its debt to operating expenses ratio is greater than that reported by just 10.97% of US equities we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Precision Biosciences Inc are MTEM, VYGR, SGMO, MRUS, and CHRS.
- Visit DTIL's SEC page to see the company's official filings. To visit the company's web site, go to www.precisionbiosciences.com.
DTIL Price Target
For more insight on analysts targets of DTIL, see our DTIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $18.50 | Average Broker Recommendation | 1.39 (Strong Buy) |
DTIL Stock Price Chart Interactive Chart >
DTIL Price/Volume Stats
| Current price | $9.50 | 52-week high | $16.60 |
| Prev. close | $9.39 | 52-week low | $4.45 |
| Day low | $9.35 | Volume | 702,030 |
| Day high | $9.91 | Avg. volume | 894,778 |
| 50-day MA | $9.65 | Dividend yield | N/A |
| 200-day MA | $8.92 | Market Cap | 546.06M |
Precision BioSciences, Inc. (DTIL) Company Bio
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Latest DTIL News From Around the Web
Below are the latest news stories about Precision Biosciences Inc that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business UpdatePrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. |
Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021. |
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual MeetingPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today that the following paper presentation, highlighting preclinical research using its ARCUS® genome editing platform for autosomal dominant Retinitis Pigmentosa (adRP), will be presented today at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. |
Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual MeetingPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS® genome editing platform for treatment of transthyretin amyloidosis (ATTR), will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 11-14, 2021. |
Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical OfficerPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences. Dr. List is a world-renowned hematologist with extensive academic and clinical experience in the research and development of hematology and oncology products. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies, including myelodysplastic syndromes, acute leukemia, multiple myeloma, and lymphoma. |
DTIL Price Returns
| 1-mo | 8.32% |
| 3-mo | -23.51% |
| 6-mo | -1.86% |
| 1-year | 30.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 13.91% |
| 2020 | -39.96% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...